Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer

Prostate cancer (PCa) deaths are typically the result of metastatic castration-resistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral AR inhibitor, was approved for treating patients with mCRPC. Invariably, all PCa patients eventually develop resistance against Enz. Therefore, novel strategies...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Carcinog
Autors principals: Peak, Taylor C., Panigrahi, Gati K, Praharaj, Prakash, Su, Yixin, Shi, Lihong, Chyr, Jacqueline, Rivera-Chávez, José, Flores-Bocanegra, Laura, Singh, Ravi, Vander Griend, Donald J., Oberlies, Nicholas H., Kerr, Bethany A., Hemal, Ashok, Bitting, Rhonda L., Deep, Gagan
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916724/
https://ncbi.nlm.nih.gov/pubmed/31674708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.23129
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars